Rhabdoid Tumor Predisposition Syndrome 2
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
|
24658001 |
2014 |
Rhabdoid Tumor Predisposition Syndrome 2
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
|
24658002 |
2014 |
COFFIN-SIRIS SYNDROME 4
|
0.600 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
COFFIN-SIRIS SYNDROME 4
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.
|
22426308 |
2012 |
Coffin-Siris syndrome
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
SMARCA4 mutations caused CSS without typical facial coarseness and with significant digital/nail hypoplasia.
|
23637025 |
2013 |
Coffin-Siris syndrome
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that SMARCA4 constitutional mutations associated with CSS are not necessarily non-truncating, and that haploinsufficiency may explain milder CSS phenotypes, as previously reported for haploinsufficient ARID1B.
|
28608987 |
2017 |
Coffin-Siris syndrome
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, mutations in the same positions were reported in malignant tumors, and a de novo missense substitution in an equivalent arginine residue in the C-terminal helicase domain of SMARCA4 is associated with Coffin Siris syndrome.
|
27616479 |
2016 |
Coffin-Siris syndrome
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
Coffin-Siris syndrome (CSS; MIM 135900) is a multisystem congenital anomaly syndrome caused by mutations in the genes in the Brg-1 associated factors (BAF) complex.
|
30276971 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemical analysis of a cohort of non-small-cell lung carcinomas (NSCLC) indicated that 15.5% (16 of 103) of the cohort, corresponding to preferentially undifferentiated tumors, was deficient in BRG1 expression.
|
23872584 |
2013 |
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we tested whether targeting one of the two mutually exclusive subdomains of the SWI/SNF complex BRM/SMARCA2 can sensitize specifically non-small cell lung carcinoma (NSCLC) cells with mutations in the other subunit BRG1/SMARCA4 toward ionizing radiation (IR).
|
30478150 |
2019 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
|
28608987 |
2017 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
|
24658004 |
2014 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
|
29102090 |
2017 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We focus on adult granulosa cell tumours (somatic monoallelic mutations in FOXL2), Sertoli-Leydig cell tumours, gynaecological embryonal rhabdomyosarcomas (germline and somatic mutations in DICER1), and small-cell carcinoma of the ovary, hypercalcaemic type (biallelic mutations in SMARCA4).
|
27504996 |
2016 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
|
25307865 |
2015 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
|
24658002 |
2014 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
|
29102090 |
2017 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
|
25307865 |
2015 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
|
24658004 |
2014 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
|
24658002 |
2014 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We focus on adult granulosa cell tumours (somatic monoallelic mutations in FOXL2), Sertoli-Leydig cell tumours, gynaecological embryonal rhabdomyosarcomas (germline and somatic mutations in DICER1), and small-cell carcinoma of the ovary, hypercalcaemic type (biallelic mutations in SMARCA4).
|
27504996 |
2016 |
Carcinoma, Small Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
|
28608987 |
2017 |
Sarcoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Newly discovered uterine sarcoma subtypes include high-grade endometrial stromal sarcomas with BCOR genetic abnormalities, fibrosarcoma-like uterine sarcomas with NTRK rearrangements and COL1A-PDGFRB fusions, as well as undifferentiated uterine sarcomas with SMARCA4 mutations.
|
31846533 |
2020 |
Burkitt Lymphoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Here, we discuss the function of histone acetyltransferases (CREBBP, EP300), histone methyltransferases (KDM2C/D, EZH2) and regulators of higher order chromatin structure (HIST1H1C/D/E, ARID1A and SMARCA4) that have been reported to be mutated in ⩾5% of DLBCL, FL or BL.
|
26473533 |
2015 |
Burkitt Lymphoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In particular, the core ATPase BRG1 is mutated in 5-10% of childhood medulloblastomas and more than 15% of Burkitt's lymphomas.
|
23698369 |
2013 |